HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

Results suggest new hope for patients with refractory chronic lymphocytic leukemia Data to support BLA submission

BARCELONA, SPAIN, June 12 ---ILEXTM Oncology, Inc. (NASDAQ: ILXO) and LeukoSite, Inc. (NASDAQ: LKST) today announced final results from an international, multi-center, pivotal Phase II clinical trial of CAMPATHR for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to fludarabine. Results of the trial were presented this weekend at the 4th Congress of the European Haematology Association (EHA) by Michael J. Keating, MB, BS, of the M.D. Anderson Cancer Center, one of the trial's principal investigators and an internationally recognized expert in CLL. The companies plan to submit a Biologics License Application (BLA) based largely on these results later this year.

"The results of this trial are encouraging," said Dr. Keating, Associate Head for Clinical Research and Professor of Medicine and internist for the Department of Leukemia at M.D. Anderson Cancer Center. "The data suggest that CAMPATH may provide an important new treatment option for fludarabine-refractory patients, a group for whom the prognosis has, to date, been extremely poor. While the treatment of patients with leukemia has relied on chemotherapeutic agents, the use of monoclonal antibodies is an innovative approach to circumventing the disease's mechanisms for resistance."

The non-comparative trial, involved 93 previously treated patients who had received prior alkylating agents and failed fludarabine therapy (median of three prior treatment regimens). For these patients, the median life expectancy is usually six to nine months.

In the trial, patients participating at the 20 clinical sites in the United States and Europe received 30 mg of CAMPATH on an outpatient basis, as an intravenous infusion, three times a week, for four to 12 weeks. The dose was gradually escalated over the first week to 30 mg, in or
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:5/24/2015)... Arizona (PRWEB) May 24, 2015 ... former Millennial Media strategy executive Jay Krihak as ... Medicx looks to ramp up its expertise and ... of the Pharmaceutical and Health sectors. , Krihak ... tech executive. Most recently, Krihak led sales planning ...
(Date:5/23/2015)... Beach, CA (PRWEB) May 23, 2015 Dr. ... Beach, California, has just posted a new article ... gauge repair. As Dr Benvenuti explained in the ... wear enlarged plugs in their earlobes. , Known as “gauging,” ... the earlobe hole, which Dr. Benvenuti said will eventually stretch ...
(Date:5/23/2015)... 2015 A live auction will be held ... surgery centers and other medical facilities around the United States. ... lab, radiology, surgery, anesthesia, exam and much more. , ... Thursday, May 28 starting at 9:00am CDT each day. The ... 25th Avenue, Melrose Park, IL 60160. Anyone can participate ...
(Date:5/22/2015)... Pioneer Millworks, the largest reclaimed wood ... designing with reclaimed wood, introducing their latest reclaimed wood ... Their newest offerings, Vat 35, Reclaimed Teak , ... to America's largest design event. , “Designers, architects, builders, ... anxious to see and feel the variety of wood ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
Breaking Medicine News(10 mins):Health News:Medicx Media Solutions Expands Executive Team 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:Ascenta Skin President Announces Plans to Grow Brand 2
(Date:5/22/2015)... 22, 2015 Electrophysiologist Kevin Makati, M.D. ... to Boston, MA to ... Heart Rhythm Society conference. These scientific sessions drew ... the ideas, people and technology that propel their ... hybrid, minimally invasive cardiac operation that combines the ...
(Date:5/22/2015)... May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), ... repair and regeneration, today announced that J.J. Finkelstein ... present a corporate overview at two upcoming investor conferences. ... SeeThruEquity 4 th Annual Microcap Conference on Thursday ... at 11:00 am EDT.  A webcast will ...
(Date:5/22/2015)... Md. , May 22, 2015  RegeneRx ... today announced a peer-reviewed publication of the results ... evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for the ... controlled adverse environment (CAE ® ) model.  The ... the results, which were previously disseminated by the ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
Cached News: